Recombinant human erythropoietin namely epoetins in combination with chemotherapeutics have been approved as alternatives for correction of anaemia in patients harbouring non‐myeloid tumours, in order to reduce the number of blood transfusions in a cancer patient.104, 105. This evidence concerns the gene EPO and anemia (phenotype).